Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 3/20 | 0.30 |
| ▸ | HTR2B | P41595 | 3/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29645993 | 1.00 | ADORA3 (0.33) | ADORA3ADORA1XDHMAPTFPR2 | |
| SCHEMBL22988384 | 0.93 | PLAT (0.34) | MAPTSCN9APDE10A | |
| SCHEMBL29645847 | 0.93 | PLAT (0.34) | MAPTSCN9APDE10A | |
| SCHEMBL22988281 | 0.91 | MAPT (0.37) | ADORA3ADORA1XDHMAPT | |
| SCHEMBL29645425 | 0.91 | MAPT (0.37) | ADORA3ADORA1XDHMAPT | |
| SCHEMBL29648555 | 0.89 | ADORA1 (0.40) | ADORA3ADORA1XDHMAPTFPR2 | |
| SCHEMBL22980234 | 0.89 | ADORA1 (0.40) | ADORA3ADORA1XDHMAPTFPR2 | |
| SCHEMBL22988343 | 0.88 | XDH (0.34) | ADORA3ADORA1XDHMAPTFPR2 | |
| SCHEMBL22980999 | 0.88 | ADORA3 (0.37) | ADORA3ADORA1XDHMAPTFPR2 | |
| SCHEMBL22979383 | 0.88 | XDH (0.34) | ADORA3ADORA1XDHMAPTFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA3 34/4885ADORA1 21/4885XDH 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.